Provided By GlobeNewswire
Last update: Apr 22, 2025
WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced findings that the actual burden of babesiosis in the United States (U.S.) may be significantly higher than Centers for Disease Control and Prevention (CDC) statistics suggest. Preliminary results of an online survey conducted by the Company showed that nearly 3 million Americans (1.26 percent of the adult population in 2020) may have received a babesiosis diagnosis from a medical practitioner in their lifetime.
Read more at globenewswire.comNASDAQ:SXTPW (7/25/2025, 2:48:38 PM)
0.0445
-0.03 (-36.25%)
NASDAQ:SXTP (7/25/2025, 3:21:49 PM)
1.325
-0.02 (-1.12%)
Find more stocks in the Stock Screener